A detailed history of Shulman De Meo Asset Management LLC transactions in Amgen Inc stock. As of the latest transaction made, Shulman De Meo Asset Management LLC holds 950 shares of AMGN stock, worth $279,803. This represents 0.08% of its overall portfolio holdings.

Number of Shares
950
Previous 950 -0.0%
Holding current value
$279,803
Previous $296,000 3.38%
% of portfolio
0.08%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

BUY
$262.75 - $319.31 $1,313 - $1,596
5 Added 0.53%
950 $296,000
Q1 2024

Apr 15, 2024

SELL
$268.87 - $324.56 $268 - $324
-1 Reduced 0.11%
945 $268,000
Q4 2023

Jan 11, 2024

SELL
$255.7 - $288.46 $8,182 - $9,230
-32 Reduced 3.27%
946 $272,000
Q3 2023

Oct 19, 2023

SELL
$218.65 - $271.46 $19,022 - $23,617
-87 Reduced 8.17%
978 $262,000
Q2 2023

Jul 26, 2023

BUY
$214.27 - $253.37 $1,714 - $2,026
8 Added 0.76%
1,065 $236,000
Q1 2023

Apr 14, 2023

SELL
$225.79 - $275.2 $2,935 - $3,577
-13 Reduced 1.21%
1,057 $255,000
Q3 2022

Oct 18, 2022

BUY
$224.46 - $253.15 $224 - $253
1 Added 0.09%
1,070 $241,000
Q2 2022

Jul 22, 2022

BUY
$230.71 - $256.74 $1,384 - $1,540
6 Added 0.56%
1,069 $260,000
Q1 2022

Apr 27, 2022

BUY
$219.27 - $242.57 $1,315 - $1,455
6 Added 0.57%
1,063 $257,000
Q4 2021

Jan 28, 2022

BUY
$198.88 - $227.6 $1,193 - $1,365
6 Added 0.57%
1,057 $238,000
Q3 2021

Oct 26, 2021

BUY
$212.27 - $248.7 $223,095 - $261,383
1,051 New
1,051 $224,000
Q2 2021

Jul 21, 2021

SELL
$233.58 - $259.14 $226,105 - $250,847
-968 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$221.91 - $258.6 $214,808 - $250,324
968 New
968 $241,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Shulman De Meo Asset Management LLC Portfolio

Follow Shulman De Meo Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shulman De Meo Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Shulman De Meo Asset Management LLC with notifications on news.